Male Sexual Dysfunction: Erectile Dysfunction (ED)

  • Nages Nagaratnam
  • Kujan Nagaratnam
  • Gary Cheuk
Reference work entry


There is a worldwide increase in erectile dysfunction. The prevalence of ED increases with age. It increases by 10% per year of age; it increased from 2% in age group 18–38 years to 48% in the over 70 years and older. Organic causes account for a large proportion of erectile dysfunction in the elderly than in the young. The clinician should appreciate the sensitivity of the situation and must avoid creating any unnecessary embarrassment and anxiety. Male erectile dysfunction has a significant impact on health-related quality of life. The review discusses the prevalence and the causes followed by evaluation and clinical management.


Erectile dysfunction Organic causes Phosphodiesterase (PDE5) inhibitors 


  1. 1.
    Nicholson A, Moreira ED Jr, Shirai M, Bin Mohd Thambi MI, Galsser DB. Epidemiology of erectile dysfunction in four countries: cross International study of the prevalence and correlates of erectile dysfunction. Urology 2003;61:201–6.CrossRefGoogle Scholar
  2. 2.
    Parazzini F, Munchini FF, Bortolotti A, Calabro A, Chatenond L, Colli E, et al. Frequency and determinants of erectile dysfunction in Italy. Eur Uol. 2000;37:43–49.CrossRefGoogle Scholar
  3. 3.
    Weber MF, Smith DP, O’Connell DL, Patel M, de Souza OL, Sitas F, et al. Risk factors for erectile dysfunction in a cohort of 108477 Australian men. MJA. 2013;199(2):107–111.PubMedGoogle Scholar
  4. 4.
    Holden C, McLachlan RI, Pitt SM, Cummg R, Wittert G, Agius PA, et al. Men in Australia: Telephone Survey (MATEeS): a national survey of the reproductive health and concerns of middle- aged and older Australian men.Lancet 2005;366:218–220.CrossRefPubMedGoogle Scholar
  5. 5.
  6. 6.
    Chew KK, Earle CM, Stuckey BGA. Erectile dysfunction in general medical practice: prevalence and clinical correlations. Int Impot. Res. 2000;12:41–45.Google Scholar
  7. 7.
    O’Keefe M, Hunt DK. Assessment and treatment of impotence. N Med Clin N Am. 1995;79:415–434.CrossRefGoogle Scholar
  8. 8.
    Buffum J. Pharmacosexology update: prescription drugs and sexual function. J Psychoactive Drugs.1986;18:97–06.CrossRefPubMedGoogle Scholar
  9. 9.
    Guay AT. Erectile dysfunction-are you prepared to discuss?. Postgrad Med. 1995;97:127–143.CrossRefGoogle Scholar
  10. 10.
    Krane RJ, Goldstrin I, Saenz de Tejada I. Impotence. N Engl J Med. 1989:321:1648–1649.CrossRefPubMedGoogle Scholar
  11. 11.
    Thase MG, Reynolds CF, Jennings JR. Nocturnal penile tumescence is diminished in depression in men. Biol Psychiatry. 1988;24:33–46.CrossRefPubMedGoogle Scholar
  12. 12.
    Andresson KE. Erectile physiological and pathophysiological pathways involved in erectile dysfunction. J Urol. 2003;170(2Pt2):S6–13.CrossRefGoogle Scholar
  13. 13.
    Kim ED. Erectile Dysfunction Workshop.
  14. 14.
    Kirby RS. Impotence: diagnosis and management of male erectile dysfunction. BMJ. 1994;308:957–61.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Fisher C, Gross J, Zuuch J. Cycle of penile erections synchronous with dreaming (REM) sleep. Arch Gen Psychiatry. 1953;12:29.CrossRefGoogle Scholar
  16. 16.
    Karacan J, Goodenough DR, Shapiro A. Erection cycle during sleep in relation to dream anxiety. Arch Gen Psychiatry. 1966;15:183.CrossRefGoogle Scholar
  17. 17.
    Lewis RW, Mayda J II. Diagnosis and treatment of vasculogenic impotence. Acta Chir Hung.1994;34:231–234.PubMedGoogle Scholar
  18. 18.
  19. 19.
    Ende J. Organic impotence. Chapter 187. Clinical Methods. The history, physical and laboratory examination. 3rd. Walker HK, Hall WD, Huest JW. Boston Butterworths,1990.Google Scholar
  20. 20.
    Priviero FB, Leite R, Webb RC, Teixeira CE. Neurophysiological basis of penile erection. Acta Pharmacol Sin. 2007;28(6):751–5.CrossRefPubMedGoogle Scholar
  21. 21.
    De Busk RF, Pepine CJ, Glasser DB, Shpilsky A, De Riesthal H, Sweeney M, et al, Efficacy and safety of sildenafil citrate in men with erectile dysfunction and stable coronary artery disease. Am J Cardiol. 2004;93:147–153.CrossRefGoogle Scholar
  22. 22.
    Shakir SAW, Wilton LW, Bochier A. Cardiovascular events in users of sildenafil: results from first phase of prescription event monitoring in England. BMJ. 2001;322:651–652.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Cheitlin MD, Hutter Am, Brindis Rg, Ganz P, Kaul S, Russell RU, et al. Use of sildenafil in patients with cardiovascular disease. J Am Coll Cardiol. 1999;33:273–282.CrossRefPubMedGoogle Scholar
  24. 24.
    Kloner R, Padma-Nathan H. Erectile dysfunction in patients with coronary artery disease. Int J Impotence Res. 2005;17:209–215.CrossRefGoogle Scholar
  25. 25.
    Latini DM, Penson DF, Colwell HH, Lubeck DP, Mehta SS, et al. Psychological impact of erectile dysfunction: validation of a new health related quality of life measure for patients with erectile dysfunction. J Urol 2002;168(5):2086–91.CrossRefPubMedGoogle Scholar
  26. 26.
    Althof SE. Quality of life and erectile dysfunction. Urology 2002;59:803–10.CrossRefPubMedGoogle Scholar
  27. 27.
    Tomlinson J, Wright D. Impact of erectile dysfunction and its subsequent treatment with sildenafil: qualitative study. BMJ 2004;328:1037.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Impotence Association. Survey 1997. London: Taylor Nelson AGB Healthcare,1997.Google Scholar
  29. 29.
    Sexual Health. Consequences of erectile dysfunction. Accessed on 8 January 2017.

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Nages Nagaratnam
    • 1
  • Kujan Nagaratnam
    • 1
  • Gary Cheuk
    • 2
  1. 1.The University of SydneyWestmead Clinical SchoolWestmeadAustralia
  2. 2.Rehabilitation and Aged Care ServiceBlacktown-Mt Druitt HospitalMount DruittAustralia

Personalised recommendations